NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.

NSC745885 (0.5-4 μM; 24 hours) enhances annexin V positive cells in a dose-dependent manner, and the differences appear as a dose-dependent manner. NSC745885 (0.5-2 μM; 24 or 48 hours) reduces XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells. NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours' treatment [1].

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment obviously decreases tumor size when compared with the vehicle control. It shows higher safety than doxorubicin[1].

4219-52-7

C14H6N2O2S

266.28

NSC745885

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years